ABL103 + pembrolizumab + taxane

ABL103 + pembrolizumab + taxane is a **triple combination therapy** under clinical investigation for advanced or metastatic solid tumors. - **ABL103** is a bispecific monoclonal antibody designed to target both B7-H4 and 4-1BB. It uses ABL Bio's Grabody-T platform to activate T cells selectively in the tumor microenvironment, aiming to reduce toxicity and enhance antitumor immune function. - **Pembrolizumab** (brand name KEYTRUDA) is a well-established anti-PD-1 monoclonal antibody checkpoint inhibitor that blocks the PD-1 pathway to restore and augment immune responses against cancer cells. - **Taxane** refers to a class of cytotoxic agents (such as paclitaxel or docetaxel) that disrupt microtubule dynamics, thereby inhibiting cell division and inducing apoptosis in cancer cells. Together, this regimen aims to both directly kill tumor cells and reprogram the immunosuppressive tumor microenvironment toward a more inflammatory, immune-active state by T cell activation and checkpoint inhibition. The combination is intended for patients whose cancers are refractory, relapsed, or intolerant to standard therapies[1][2][3][4][5][6][7][8].

Brand names

Keytruda

Other names

ABL103 + pembrolizumab + taxane